• Phone: +1-631-791-1145
  • Email: sales@imarcgroup.com

*As the coronavirus disease (COVID-19) crisis takes over the world, we are continuously tracking the changes in the markets, as well as the purchase behaviours of the consumers globally and our estimates about the latest market trends and forecasts are being done after considering the impact of this pandemic.

Cancer Monoclonal Antibodies Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025

The global cancer monoclonal antibodies market is currently witnessing strong growth. A cancer monoclonal antibody refers to a laboratory-generated molecule that is engineered to mimic the immune system’s attack on cancer cells. It can bind to antigens present on the surface of cancer cells and flag them to trigger the destruction of cell membranes, block cell growth and immune system inhibitors. It can also deliver treatment radiations directly to the cancer cells to neutralize or destroy them. Some of the most commonly used monoclonal antibodies include murine, chimeric and humanized antibodies that are employed in the treatment of cancer in the blood, liver, brain and breast.

The increasing prevalence of cancer across the globe is one of the key factors driving the growth of the market. In comparison to traditionally used non-targeted therapies, such as chemotherapy, monoclonal antibodies have reduced side-effects on the patient’s body and can also be used for the treatment of autoimmune and inflammatory diseases. Furthermore, widespread adoption of cost-efficient biosimilar monoclonal antibodies by medical practitioners and oncologists is also providing a boost to the market growth. With technological advancements in gene sequencing and target gene selection, these antibodies can be modified to have similar properties to that of a pharmaceutical drug. They have the same efficiency but are available at reduced prices than the original medicine, which aids in enhancing the cost-efficiency of the treatment, thereby contributing to the increasing demand for the product across the globe. Other factors, including rising preference for personalized medicines, extensive research and development (R&D) activities and significant improvements in the healthcare infrastructure, are projected to drive the market further. Looking forward, IMARC Group expects the global cancer monoclonal antibodies market to continue its strong growth during the next five years.

Breakup by Antibody Type:

  • Murine Antibodies
  • Chimeric Antibodies
  • Humanized Antibodies
  • Others
     

Breakup by Medication Type:

  • Bevacizumab (Avastin)
  • Rituximab (Rituxan)
  • Trastuzumab (Herceptin)
  • Cetuximab (Erbitux)
  • Panitumumab (Vectibix)
  • Others
     

Breakup by Application:

  • Breast Cancer
  • Blood Cancer
  • Liver Cancer
  • Brain Cancer
  • Colorectal Cancer
  • Others
     

Breakup by End-User:

  • Hospitals and Clinics
  • Pharmacies
  • Research Laboratories
  • Others
     

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa
     

Competitive Landscape:

The competitive landscape of the industry has also been examined with some of the key players being AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Genmab A/S, GlaxoSmithKline Plc., Johnson & Johnson, Merck & Co. Inc., Novartis AG, Pfizer Inc., Roche Holding AG, Seattle Genetics Inc., Spectrum Pharmaceuticals Inc., etc.

Key Questions Answered in This Report:

  • How has the global cancer monoclonal antibodies market performed so far and how will it perform in the coming years?
  • What are the key regional markets?
  • What has been the impact of COVID-19 on the global cancer monoclonal antibodies market?
  • What is the breakup of the market based on the antibody type?
  • What is the breakup of the market based on the medication type?
  • What is the breakup of the market based on the application?
  • What is the breakup of the market based on the end-user?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global cancer monoclonal antibodies market and who are the key players?
  • What is the degree of competition in the industry?

1    Preface
2    Scope and Methodology 

    2.1    Objectives of the Study
    2.2    Stakeholders
    2.3    Data Sources
        2.3.1    Primary Sources
        2.3.2    Secondary Sources
    2.4    Market Estimation
        2.4.1    Bottom-Up Approach
        2.4.2    Top-Down Approach
    2.5    Forecasting Methodology
3    Executive Summary
4    Introduction

    4.1    Overview
    4.2    Key Industry Trends
5    Global Cancer Monoclonal Antibodies Market
    5.1    Market Overview
    5.2    Market Performance
    5.3    Impact of COVID-19
    5.4    Market Forecast
6    Market Breakup by Antibody Type
    6.1    Murine Antibodies
        6.1.1 Market Trends
        6.1.2 Market Forecast
    6.2    Chimeric Antibodies
        6.2.1 Market Trends
        6.2.2 Market Forecast
    6.3    Humanized Antibodies
        6.3.1 Market Trends
        6.3.2 Market Forecast
    6.4    Others
        6.4.1 Market Trends
        6.4.2 Market Forecast
7    Market Breakup by Medication Type
    7.1    Bevacizumab (Avastin)
        7.1.1 Market Trends
        7.1.2 Market Forecast
    7.2    Rituximab (Rituxan)
        7.2.1 Market Trends
        7.2.2 Market Forecast
    7.3    Trastuzumab (Herceptin)
        7.3.1 Market Trends
        7.3.2 Market Forecast
    7.4    Cetuximab (Erbitux)
        7.4.1 Market Trends
        7.4.2 Market Forecast
    7.5    Panitumumab (Vectibix)
        7.5.1 Market Trends
        7.5.2 Market Forecast
    7.6    Others
        7.6.1 Market Trends
        7.6.2 Market Forecast
8    Market Breakup by Application
    8.1    Breast Cancer
        8.1.1 Market Trends
        8.1.2 Market Forecast
    8.2    Blood Cancer
        8.2.1 Market Trends
        8.2.2 Market Forecast
    8.3    Liver Cancer
        8.3.1 Market Trends
        8.3.2 Market Forecast
    8.4    Brain Cancer
        8.4.1 Market Trends
        8.4.2 Market Forecast
    8.5    Colorectal Cancer
        8.5.1 Market Trends
        8.5.2 Market Forecast
    8.6    Others
        8.6.1 Market Trends
        8.6.2 Market Forecast
9    Market Breakup by End-User
    9.1    Hospitals and Clinics
        9.1.1 Market Trends
        9.1.2 Market Forecast
    9.2    Pharmacies
        9.2.1 Market Trends
        9.2.2 Market Forecast
    9.3    Research Laboratories
        9.3.1 Market Trends
        9.3.2 Market Forecast
    9.4    Others
        9.4.1 Market Trends
        9.4.2 Market Forecast
10    Market Breakup by Region
    10.1    North America
        10.1.1 United States
           10.1.1.1 Market Trends
           10.1.1.2 Market Forecast
        10.1.2 Canada
           10.1.2.1 Market Trends
           10.1.2.2 Market Forecast
    10.2    Asia Pacific
        10.2.1 China
           10.2.1.1 Market Trends
           10.2.1.2 Market Forecast
        10.2.2 Japan
           10.2.2.1 Market Trends
           10.2.2.2 Market Forecast
        10.2.3 India
           10.2.3.1 Market Trends
           10.2.3.2 Market Forecast
        10.2.4 South Korea
           10.2.4.1 Market Trends
           10.2.4.2 Market Forecast
        10.2.5 Australia
           10.2.5.1 Market Trends
           10.2.5.2 Market Forecast
        10.2.6 Others
           10.2.6.1 Market Trends
           10.2.6.2 Market Forecast
    10.3    Europe
        10.3.1 Germany
           10.3.1.1 Market Trends
           10.3.1.2 Market Forecast
        10.3.2 France
           10.3.2.1 Market Trends
           10.3.2.2 Market Forecast
        10.3.3 United Kingdom
           10.3.3.1 Market Trends
           10.3.3.2 Market Forecast
        10.3.4 Italy
           10.3.4.1 Market Trends
           10.3.4.2 Market Forecast
        10.3.5 Spain
           10.3.5.1 Market Trends
           10.3.5.2 Market Forecast
        10.3.6 Russia
           10.3.6.1 Market Trends
           10.3.6.2 Market Forecast
        10.3.7 Others
           10.3.7.1 Market Trends
           10.3.7.2 Market Forecast
    10.4    Latin America
        10.4.1 Brazil
           10.4.1.1 Market Trends
           10.4.1.2 Market Forecast
        10.4.2 Mexico
           10.4.2.1 Market Trends
           10.4.2.2 Market Forecast
        10.4.3 Others
           10.4.3.1 Market Trends
           10.4.3.2 Market Forecast
    10.5    Middle East and Africa
        10.5.1 Market Trends
        10.5.2 Market Breakup by Country
        10.5.3 Market Forecast
11    SWOT Analysis
    11.1    Overview
    11.2    Strengths
    11.3    Weaknesses
    11.4    Opportunities
    11.5    Threats
12    Value Chain Analysis
13    Porters Five Forces Analysis

    13.1    Overview
    13.2    Bargaining Power of Buyers
    13.3    Bargaining Power of Suppliers
    13.4    Degree of Competition
    13.5    Threat of New Entrants
    13.6    Threat of Substitutes
14    Competitive Landscape
    14.1    Market Structure
    14.2    Key Players
    14.3    Profiles of Key Players
        14.3.1    Amgen Inc.
           14.3.1.1 Company Overview
           14.3.1.2 Product Portfolio 
           14.3.1.3 Financials
           14.3.1.4 SWOT Analysis
        14.3.2    Roche Holding AG
           14.3.2.1 Company Overview
           14.3.2.2 Product Portfolio 
           14.3.2.3 Financials 
        14.3.3    AbbVie Inc.
           14.3.3.1 Company Overview
           14.3.3.2 Product Portfolio 
           14.3.3.3 Financials
           14.3.3.4 SWOT Analysis
        14.3.4    Johnson & Johnson
           14.3.4.1 Company Overview
           14.3.4.2 Product Portfolio 
           14.3.4.3 Financials
           14.3.4.4 SWOT Analysis
        14.3.5    Eli Lilly and Company
           14.3.5.1 Company Overview
           14.3.5.2 Product Portfolio 
           14.3.5.3 Financials
           14.3.5.4 SWOT Analysis
        14.3.6    Merck & Co., Inc.
           14.3.6.1 Company Overview
           14.3.6.2 Product Portfolio 
           14.3.6.3 Financials
           14.3.6.4 SWOT Analysis
        14.3.7    Genmab A/S
           14.3.7.1 Company Overview
           14.3.7.2 Product Portfolio 
           14.3.7.3 Financials
           14.3.7.4 SWOT Analysis
        14.3.8    GlaxoSmithKline Plc.
           14.3.8.1 Company Overview
           14.3.8.2 Product Portfolio 
           14.3.8.3 Financials
           14.3.8.4 SWOT Analysis
        14.3.9    Bristol-Myers Squibb Company
           14.3.9.1 Company Overview
           14.3.9.2 Product Portfolio 
           14.3.9.3 Financials
           14.3.9.4 SWOT Analysis
        14.3.10    Novartis AG
           14.3.10.1 Company Overview
           14.3.10.2 Product Portfolio 
           14.3.10.3 Financials
           14.3.10.4 SWOT Analysis
        14.3.11    Spectrum Pharmaceuticals Inc.
           14.3.11.1 Company Overview
           14.3.11.2 Product Portfolio 
           14.3.11.3 Financials
           14.3.11.4 SWOT Analysis
        14.3.12    Seattle Genetics Inc.
           14.3.12.1 Company Overview
           14.3.12.2 Product Portfolio 
           14.3.12.3 Financials
           14.3.12.4 SWOT Analysis
        14.3.13    Pfizer Inc.
           14.3.13.1 Company Overview
           14.3.13.2 Product Portfolio 
           14.3.13.3 Financials
           14.3.13.4 SWOT Analysis

List of Figures

Figure 1: Global: Cancer Monoclonal Antibodies Market: Major Drivers and Challenges
Figure 2: Global: Cancer Monoclonal Antibodies Market: Sales Value (in Billion US$), 2014-2019
Figure 3: Global: Cancer Monoclonal Antibodies Market: Breakup by Antibody Type (in %), 2019
Figure 4: Global: Cancer Monoclonal Antibodies Market: Breakup by Medication Type (in %), 2019
Figure 5: Global: Cancer Monoclonal Antibodies Market: Breakup by Application (in %), 2019 
Figure 6: Global: Cancer Monoclonal Antibodies Market: Breakup by End-User (in %), 2019
Figure 7: Global: Cancer Monoclonal Antibodies Market: Breakup by Region (in %), 2019
Figure 8: Global: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Billion US$), 2020-2025
Figure 9: Global: Cancer Monoclonal Antibodies (Murine Antibodies) Market: Sales Value (in Million US$), 2014 & 2019
Figure 10: Global: Cancer Monoclonal Antibodies (Murine Antibodies) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 11: Global: Cancer Monoclonal Antibodies (Chimeric Antibodies) Market: Sales Value (in Million US$), 2014 & 2019
Figure 12: Global: Cancer Monoclonal Antibodies (Chimeric Antibodies) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 13: Global: Cancer Monoclonal Antibodies (Humanized Antibodies) Market: Sales Value (in Million US$), 2014 & 2019
Figure 14: Global: Cancer Monoclonal Antibodies (Humanized Antibodies) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 15: Global: Cancer Monoclonal Antibodies (Other Types of Antibodies) Market: Sales Value (in Million US$), 2014 & 2019
Figure 16: Global: Cancer Monoclonal Antibodies (Other Types of Antibodies) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 17: Global: Cancer Monoclonal Antibodies (Bevacizumab) Market: Sales Value (in Million US$), 2014 & 2019
Figure 18: Global: Cancer Monoclonal Antibodies (Bevacizumab) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 19: Global: Cancer Monoclonal Antibodies (Rituximab) Market: Sales Value (in Million US$), 2014 & 2019
Figure 20: Global: Cancer Monoclonal Antibodies (Rituximab) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 21: Global: Cancer Monoclonal Antibodies (Trastuzumab) Market: Sales Value (in Million US$), 2014 & 2019
Figure 22: Global: Cancer Monoclonal Antibodies (Trastuzumab) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 23: Global: Cancer Monoclonal Antibodies (Cetuximab) Market: Sales Value (in Million US$), 2014 & 2019
Figure 24: Global: Cancer Monoclonal Antibodies (Cetuximab) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 25: Global: Cancer Monoclonal Antibodies (Panitumumab) Market: Sales Value (in Million US$), 2014 & 2019
Figure 26: Global: Cancer Monoclonal Antibodies (Panitumumab) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 27: Global: Cancer Monoclonal Antibodies (Other Medication Types) Market: Sales Value (in Million US$), 2014 & 2019
Figure 28: Global: Cancer Monoclonal Antibodies (Other Medication Types) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 29: Global: Cancer Monoclonal Antibodies (Breast Cancer) Market: Sales Value (in Million US$), 2014 & 2019
Figure 30: Global: Cancer Monoclonal Antibodies (Breast Cancer) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 31: Global: Cancer Monoclonal Antibodies (Blood Cancer) Market: Sales Value (in Million US$), 2014 & 2019
Figure 32: Global: Cancer Monoclonal Antibodies (Blood Cancer) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 33: Global: Cancer Monoclonal Antibodies (Liver Cancer) Market: Sales Value (in Million US$), 2014 & 2019
Figure 34: Global: Cancer Monoclonal Antibodies (Liver Cancer) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 35: Global: Cancer Monoclonal Antibodies (Brain Cancer) Market: Sales Value (in Million US$), 2014 & 2019
Figure 36: Global: Cancer Monoclonal Antibodies (Brain Cancer) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 37: Global: Cancer Monoclonal Antibodies (Colorectal Cancer) Market: Sales Value (in Million US$), 2014 & 2019
Figure 38: Global: Cancer Monoclonal Antibodies (Colorectal Cancer) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 39: Global: Cancer Monoclonal Antibodies (Other Applications) Market: Sales Value (in Million US$), 2014 & 2019
Figure 40: Global: Cancer Monoclonal Antibodies (Other Applications) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 41: Global: Cancer Monoclonal Antibodies (Hospitals and Clinics) Market: Sales Value (in Million US$), 2014 & 2019
Figure 42: Global: Cancer Monoclonal Antibodies (Hospitals and Clinics) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 43: Global: Cancer Monoclonal Antibodies (Pharmacies) Market: Sales Value (in Million US$), 2014 & 2019
Figure 44: Global: Cancer Monoclonal Antibodies (Pharmacies) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 45: Global: Cancer Monoclonal Antibodies (Research Laboratories) Market: Sales Value (in Million US$), 2014 & 2019
Figure 46: Global: Cancer Monoclonal Antibodies (Research Laboratories) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 47: Global: Cancer Monoclonal Antibodies (Others) Market: Sales Value (in Million US$), 2014 & 2019
Figure 48: Global: Cancer Monoclonal Antibodies (Others) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 49: North America: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2014 & 2019
Figure 50: North America: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 51: United States: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2014 & 2019
Figure 52: United States: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 53: Canada: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2014 & 2019
Figure 54: Canada: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 55: Asia Pacific: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2014 & 2019
Figure 56: Asia Pacific: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 57: China: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2014 & 2019
Figure 58: China: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 59: Japan: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2014 & 2019
Figure 60: Japan: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 61: India: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2014 & 2019
Figure 62: India: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 63: South Korea: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2014 & 2019
Figure 64: South Korea: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 65: Australia: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2014 & 2019
Figure 66: Australia: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 67: Others: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2014 & 2019
Figure 68: Others: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 69: Europe: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2014 & 2019
Figure 70: Europe: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 71: Germany: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2014 & 2019
Figure 72: Germany: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 73: France: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2014 & 2019
Figure 74: France: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 75: United Kingdom: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2014 & 2019
Figure 76: United Kingdom: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 77: Italy: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2014 & 2019
Figure 78: Italy: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 79: Spain: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2014 & 2019
Figure 80: Spain: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 81: Russia: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2014 & 2019
Figure 82: Russia: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 83: Others: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2014 & 2019
Figure 84: Others: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 85: Latin America: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2014 & 2019
Figure 86: Latin America: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 87: Brazil: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2014 & 2019
Figure 88: Brazil: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 89: Mexico: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2014 & 2019
Figure 90: Mexico: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 91: Others: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2014 & 2019
Figure 92: Others: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 93: Middle East and Africa: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2014 & 2019
Figure 94: Middle East and Africa: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 95: Global: Cancer Monoclonal Antibodies Industry: SWOT Analysis
Figure 96: Global: Cancer Monoclonal Antibodies Industry: Value Chain Analysis
Figure 97: Global: Cancer Monoclonal Antibodies Industry: Porter’s Five Forces Analysis

List of Tables

Table 1: Global: Cancer Monoclonal Antibodies Market: Key Industry Highlights, 2019 and 2025
Table 2: Global: Cancer Monoclonal Antibodies Market Forecast: Breakup by Antibody Type (in Million US$), 2020-2025
Table 3: Global: Cancer Monoclonal Antibodies Market Forecast: Breakup by Medication Type (in Million US$), 2020-2025
Table 4: Global: Cancer Monoclonal Antibodies Market Forecast: Breakup by Application (in Million US$), 2020-2025
Table 5: Global: Cancer Monoclonal Antibodies Market Forecast: Breakup by End-User (in Million US$), 2020-2025
Table 6: Global: Cancer Monoclonal Antibodies Market Forecast: Breakup by Region (in Million US$), 2020-2025
Table 7: Global: Cancer Monoclonal Antibodies Market: Competitive Structure
Table 8: Global: Cancer Monoclonal Antibodies Market: Key Players        

Note: We value your privacy and will never rent or sell your email address. Privacy policy

Purchase Options




$ 2299

REACH OUT TO US

Call us on

( US: +1-631-791-1145 )
( UK: +44-702-409-7331 )
( India: +91-120-433-0800 )


Drop us an email at

sales@imarcgroup.com

Social Links